These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 8531430)

  • 1. [The current principles of the conservative treatment of patients with benign prostatic hypertrophy].
    Ianev V; Milushev N
    Khirurgiia (Sofiia); 1994; 47(3):36-8. PubMed ID: 8531430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [5-alpha-reductase inhibitors in benign prostatic hyperplasia].
    Panchev P; Neĭkov K
    Khirurgiia (Sofiia); 1997; 50(1):41-3. PubMed ID: 9379618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The long-term treatment of patients with benign prostatic hyperplasia using Proscar].
    Lopatkin NA; Roilans PJ; Stoner E
    Urol Nefrol (Mosk); 1996; (1):2-4. PubMed ID: 8659035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New agents developed for the treatment of benign prostatic hyperplasia].
    Akakura K
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():373-7. PubMed ID: 12599603
    [No Abstract]   [Full Text] [Related]  

  • 6. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H; Kanetake H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B; McConnell J
    Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proscar (finasteride, MSD) in the treatment of patients with prostatic hyperplasia].
    Pytel' IuA; Vinarov AZ
    Urol Nefrol (Mosk); 1996; (4):25-7. PubMed ID: 8928344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2002; (1):19-22. PubMed ID: 11877966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Benign prostatic hyperplasia--its treatment with Proscar].
    Panchev P; Neĭkov K; Simeonov P
    Khirurgiia (Sofiia); 1996; 49(1):15-8. PubMed ID: 8975081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P
    J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finasteride in the treatment of benign prostatic hyperplasia.
    Ekman P; Andersen JT; Wolf H
    Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
    Levine AC; Kirschenbaum A; Gabrilove JL
    Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
    N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment of BPH.
    Roylance P; Gibelin B; Espié J
    Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA
    Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.